Breaking News Instant updates and real-time market news.

YETI

Yeti

$18.66

0.25 (1.36%)

06:06
02/14/19
02/14
06:06
02/14/19
06:06

Yeti sees FY19 adjusted EPS 99c-$1.04, consensus 96c

Sees FY19 Net sales increasing between 11.5%-13% compared to fiscal 2018 with growth across both channels led by the DTC channel, consensus $867.76M.

  • 14

    Feb

YETI Yeti
$18.66

0.25 (1.36%)

01/14/19
BARD
01/14/19
NO CHANGE
Target $23
BARD
Outperform
Yeti bullish thesis reinforced by Q4 update, says Baird
Baird analyst Peter Benedict noted Yeti provided a positive Q4 update which he said reinforces his bullish thesis. The analyst believes the company is on track to be a $1B brand within the next 2-3 years as rising brand awareness, ongoing product innovation, and a broadening geographic footprint will support its growth. Benedict reiterated his Outperform rating and $23 price target on Yeti shares.
01/14/19
JEFF
01/14/19
NO CHANGE
Target $35
JEFF
Buy
Yeti target raised to $35 after 'strong' Q4 at Jefferies
Yeti's preliminary Q4 results were strong, as the brand continues to gain credibility in non-core categories and mix shifts favorably to direct-to-consumer, Jefferies analyst Randal Konik tells investors in a post-earnings research note. The analyst sees "significant opportunity" for Yeti to expand its total addressable market and boosted his price target for the shares to $35 from $34. He keeps a Buy rating on the name.
01/15/19
PIPR
01/15/19
NO CHANGE
Target $25
PIPR
Overweight
Piper ups Yeti target to $25, calls valuation 'very reasonable'
Piper Jaffray analyst Peter Keith views Yeti's preliminary Q4 results as strong and indicative of potential sales and margin upside the company can drive going forward. Importantly, high margin direct-to-consumer sales drove most of the upside, as Yeti appears to be leveraging its recently launched national advertising, Keith tells investors in a research note after meeting with management. He continues to view the stock's valuation as "very reasonable" given the company's "strong fundamentals." The analyst raised his price target for Yeti to $25 from $24 and reiterates an Overweight rating on the name.
01/15/19
BARD
01/15/19
NO CHANGE
Target $23
BARD
Outperform
Fresh Pick designation removed from Yeti, Outperform rating reiterated at Baird
Baird analyst Peter Benedict closed out his Fresh Pick designation on Yeti as his associated tactical catalysts have unfolded. The analyst said he continues to see significant upside opportunity for the shares longer-term as brand awareness grows and ongoing product innovation expands. Benedict reiterated his Outperform rating and $23 price target on Yeti shares.

TODAY'S FREE FLY STORIES

ARAY

Accuray

$5.26

0.09 (1.74%)

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Hot Stocks
Accuray reports results from SBRT trial »

Accuray announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$64.31

-0.35 (-0.54%)

07:36
02/22/19
02/22
07:36
02/22/19
07:36
Upgrade
Citi rating change  »

Jefferies sees positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Apr

  • 28

    May

  • 13

    Jul

BCLI

BrainStorm

$3.88

0.01 (0.26%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Hot Stocks
BrainStorm announces first U.S.clinical site for Phase 2 MS study »

BrainStorm announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPC

W.P. Carey

$74.39

0.25 (0.34%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Earnings
Breaking Earnings news story on W.P. Carey »

W.P. Carey sees FY19 AFFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

KEYS

Keysight Technologies

$81.74

0.67 (0.83%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Recommendations
Keysight Technologies analyst commentary  »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WFT

Weatherford

$0.78

-0.0436 (-5.32%)

, KR

Kroger

$28.55

-0.2 (-0.70%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

WFT

Weatherford

$0.78

-0.0436 (-5.32%)

KR

Kroger

$28.55

-0.2 (-0.70%)

I

Intelsat

$24.59

0.5 (2.08%)

BSX

Boston Scientific

$40.12

-0.01 (-0.02%)

OAS

Oasis Petroleum

$6.07

-0.28 (-4.41%)

MNST

Monster Beverage

$58.87

0.16 (0.27%)

LKQ

LKQ Corp.

$27.33

0.36 (1.33%)

DK

Delek US

$36.18

-0.8953 (-2.41%)

AGI

Alamos Gold

$4.82

-0.055 (-1.13%)

APEI

American Public Education

$32.93

0.88 (2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 28

    Mar

  • 18

    May

  • 22

    May

  • 28

    May

07:35
02/22/19
02/22
07:35
02/22/19
07:35
General news
Treasury Market Outlook: yields are lower in the U.S. and Europe »

Treasury Market Outlook:…

WPC

W.P. Carey

$74.39

0.25 (0.34%)

07:34
02/22/19
02/22
07:34
02/22/19
07:34
Earnings
W.P. Carey reports Q4 AFFO $1.33, consensus $1.33 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BXG

Bluegreen Vacations

$13.92

-0.12 (-0.85%)

07:34
02/22/19
02/22
07:34
02/22/19
07:34
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TEF

Telefonica

$8.85

0.12 (1.37%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Hot Stocks
EU says Telefonica breached commitment in E-Plus acquisition »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CONE

CyrusOne

$52.44

-4.75 (-8.31%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Recommendations
CyrusOne analyst commentary  »

CyrusOne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 18

    Jun

BIIB

Biogen

$320.99

-14.02 (-4.18%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    May

INSM

Insmed

$25.57

-0.42 (-1.62%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Hot Stocks
Insmed sees FY19 ARIKAYCE revenues $80M-$90M »

Insmed expects cash-based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

OPNT

Opiant Pharmaceuticals

$14.65

-0.25 (-1.68%)

07:32
02/22/19
02/22
07:32
02/22/19
07:32
Recommendations
Opiant Pharmaceuticals analyst commentary  »

Opiant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$418.66

-3.9 (-0.92%)

07:32
02/22/19
02/22
07:32
02/22/19
07:32
Downgrade
Regeneron rating change  »

Regeneron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

  • 11

    Mar

  • 28

    Apr

  • 13

    May

INSM

Insmed

$25.57

-0.42 (-1.62%)

07:31
02/22/19
02/22
07:31
02/22/19
07:31
Earnings
Insmed reports Q4 EPS ($1.19), consensus ($1.06) »

Reports Q4 revenue $9.8M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SHW

Sherwin-Williams

$438.49

0.56 (0.13%)

07:31
02/22/19
02/22
07:31
02/22/19
07:31
Recommendations
Sherwin-Williams analyst commentary  »

Sherwin-Williams price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZGNX

Zogenix

$47.88

0.35 (0.74%)

07:30
02/22/19
02/22
07:30
02/22/19
07:30
Initiation
Zogenix initiated  »

Zogenix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$10.03

-0.07 (-0.69%)

, JNJ

Johnson & Johnson

$135.40

-0.91 (-0.67%)

07:30
02/22/19
02/22
07:30
02/22/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$10.03

-0.07 (-0.69%)

JNJ

Johnson & Johnson

$135.40

-0.91 (-0.67%)

M

Macy's

$24.44

-0.58 (-2.32%)

CZR

Caesars

$9.42

-0.21 (-2.18%)

KEM

Kemet

$18.87

-0.56 (-2.88%)

COUP

Coupa Software

$92.20

-1.55 (-1.65%)

SM

SM Energy

$17.01

-2.69 (-13.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 03

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

ROKU

Roku

$51.47

-2.16 (-4.03%)

07:29
02/22/19
02/22
07:29
02/22/19
07:29
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SM

SM Energy

$17.01

-2.69 (-13.65%)

07:29
02/22/19
02/22
07:29
02/22/19
07:29
Recommendations
SM Energy analyst commentary  »

SM Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$79.82

0.38 (0.48%)

07:28
02/22/19
02/22
07:28
02/22/19
07:28
Initiation
Merck initiated  »

Merck initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

  • 18

    May

  • 17

    Jun

SAGE

Sage Therapeutics

$146.14

-1.32 (-0.90%)

07:28
02/22/19
02/22
07:28
02/22/19
07:28
Initiation
Sage Therapeutics initiated  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 19

    Mar

BMRN

BioMarin

$88.80

-1.82 (-2.01%)

07:26
02/22/19
02/22
07:26
02/22/19
07:26
Recommendations
BioMarin analyst commentary  »

BioMarin base business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$19.59

1 (5.38%)

07:26
02/22/19
02/22
07:26
02/22/19
07:26
Initiation
RA Pharmaceuticals initiated  »

RA Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.